New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - water for injection 100%{vol} - solution for injection - active: water for injection 100%{vol} - water for injection bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injection bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - macrogol 3350 52.9 g;  ; potassium chloride 740mg; sodium chloride 2.6 g; sodium sulfate 5.6 g; citric acid 12.2 g; magnesium carbonate monohydrate 7.4 g; sodium picosulfate 10.3mg - combination - active: macrogol 3350 52.9 g   potassium chloride 740mg sodium chloride 2.6 g sodium sulfate 5.6 g excipient: ascorbic acid colloidal silicon dioxide orange flavour facb076 sweetener sweetesse 97 active: citric acid 12.2 g magnesium carbonate monohydrate 7.4 g sodium picosulfate 10.3mg excipient: orange flavour facb076 sweetener sweetesse 97 - prepkit orange is indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (ivp) or colorectal surgery, in adults 18 years and over.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - chromium trichloride hexahydrate 5.33 µg/ml;  ; copper chloride dihydrate 0.34 mg/ml;  ; ferric chloride hexahydrate 0.54 mg/ml;  ; manganese chloride tetrahydrate 99 µg/ml;  ; potassium iodide 16.6 µg/ml; sodium fluoride 0.21 mg/ml; sodium molybdate dihydrate 4.85 µg/ml;  ; sodium selenite 10.5 µg/ml;  ;  ; zinc chloride 1.36 mg/ml;  ;  ; chromium trichloride hexahydrate 5.33 µg/ml; copper chloride dihydrate 102.3 µg/ml; ferric chloride hexahydrate 540 µg/ml; manganese chloride tetrahydrate 19.79 µg/ml; potassium iodide 16.6 µg/ml; sodium fluoride 210 µg/ml; sodium molybdate dihydrate 4.85 µg/ml; sodium selenite 17.29 µg/ml; zinc chloride 1050 µg/ml - solution for infusion - active: chromium trichloride hexahydrate 5.33 µg/ml   copper chloride dihydrate 0.34 mg/ml   ferric chloride hexahydrate 0.54 mg/ml   manganese chloride tetrahydrate 99 µg/ml   potassium iodide 16.6 µg/ml sodium fluoride 0.21 mg/ml sodium molybdate dihydrate 4.85 µg/ml   sodium selenite 10.5 µg/ml     zinc chloride 1.36 mg/ml     excipient: hydrochloric acid water for injection xylitol active: chromium trichloride hexahydrate 5.33 µg/ml copper chloride dihydrate 102.3 µg/ml ferric chloride hexahydrate 540 µg/ml manganese chloride tetrahydrate 19.79 µg/ml potassium iodide 16.6 µg/ml sodium fluoride 210 µg/ml sodium molybdate dihydrate 4.85 µg/ml sodium selenite 17.29 µg/ml zinc chloride 1050 µg/ml excipient: hydrochloric acid water for injection xylitol - to meet basal to moderately increased requirements of trace elements in parenteral nutrition in adults and children weighing 15 kg and over, when either oral or enteral nutrition is inappropriate

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium glycerophosphate pentahydrate 306.1 mg/ml (corresponds to sodium glycerophosphate anhydrous 216 mg/ml - ) - concentrate for infusion - 306.1 mg/ml - active: sodium glycerophosphate pentahydrate 306.1 mg/ml (corresponds to sodium glycerophosphate anhydrous 216 mg/ml - ) excipient: hydrochloric acid water for injection - glycophos is indicated in adult patients, children, infants and neonates as a supplement in intravenous nutrition to meet the requirement of phosphate.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: sodium sulfate; sulfuric acid; sodium acetate trihydrate; water for injections - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetate trihydrate; sodium sulfate; sulfuric acid - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cefepime hydrochloride monohydrate, quantity: 1189.2 mg (equivalent: cefepime, qty 1 g) - injection, powder for - excipient ingredients: arginine - adults: cefepime kabi is indicated in the treatment of the infections listed below when caused by susceptible bacteria.,- lower respiratory tract infections, including pneumonia and bronchitis. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. - intra-abdominal infections, including peritonitis and biliary tract infections. - gynaecological infections. - septicaemia. - empiric treatment in febrile neutropenic patients (see precautions).,cefepime kabi is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.,paediatrics: cefepime kabi is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria: - pneumonia. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. - septicaemia. - empiric treatment in febrile neutropenic patients (see precautions).,culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empiric therapy with cefepime kabi may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.,because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, cefepime kabi can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime kabi. in patients who are at risk of mixed aerobic-anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cefepime hydrochloride monohydrate, quantity: 2378.5 mg (equivalent: cefepime, qty 2 g) - injection, powder for - excipient ingredients: arginine - adults: cefepime kabi is indicated in the treatment of the infections listed below when caused by susceptible bacteria.,- lower respiratory tract infections, including pneumonia and bronchitis. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. - intra-abdominal infections, including peritonitis and biliary tract infections. - gynaecological infections. - septicaemia. - empiric treatment in febrile neutropenic patients (see precautions).,cefepime kabi is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.,paediatrics: cefepime kabi is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria: - pneumonia. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - skin and skin structure infections. - septicaemia. - empiric treatment in febrile neutropenic patients (see precautions).,culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empiric therapy with cefepime kabi may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.,because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, cefepime kabi can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime kabi. in patients who are at risk of mixed aerobic-anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flumazenil, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: acetic acid; sodium hydroxide; disodium edetate; sodium chloride; water for injections - flumazenil kabi is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flumazenil, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: water for injections; acetic acid; sodium chloride; sodium hydroxide; disodium edetate - flumazenil kabi is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil. not to be used in outpatients or short stay patients. not to be used as a diagnostic.